Temporal patterns of chronic disease incidence after breast cancer: a nationwide population-based cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Danbee | - |
dc.contributor.author | Kang, Minwoong | - |
dc.contributor.author | Hong, Yun Soo | - |
dc.contributor.author | Park, Jihwan | - |
dc.contributor.author | Lee, Jin | - |
dc.contributor.author | Seo, Hwa Jeong | - |
dc.contributor.author | Kim, Dong Wook | - |
dc.contributor.author | Ahn, Jin Seok | - |
dc.contributor.author | Park, Yeon Hee | - |
dc.contributor.author | Lee, Se Kyung | - |
dc.contributor.author | Shin, Dong Wook | - |
dc.contributor.author | Guallar, Eliseo | - |
dc.contributor.author | Cho, Juhee | - |
dc.date.accessioned | 2022-04-22T03:40:25Z | - |
dc.date.available | 2022-04-22T03:40:25Z | - |
dc.date.created | 2022-04-22 | - |
dc.date.issued | 2022-03-31 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/84083 | - |
dc.description.abstract | We conducted a retrospective cohort study to evaluate the temporal pattern of incidence of chronic conditions after developing breast cancer using a population-based national registry. We selected 84,969 women with newly diagnosed breast cancer between 2002 and 2016 and a 1:10 sample of age-matched non-breast cancer controls (N = 1,057,674). The main study exposure was incident breast cancer, considered as a time-varying exposure. The outcomes were incident cases of leukemia, endometrial cancer, myeloma, cardiomyopathy, osteoporosis, end stage renal disease (ESRD), pulmonary fibrosis, hypothyroidism, type 2 diabetes, hypertension and hyperlipidemia. The development of breast cancer was associated with a significantly increased risk of all outcomes analyzed except for ESRD and hypertension. The fully-adjusted risks of leukemia (HR 3.09; 95% CI 2.11-4.51), cardiomyopathy (HR 2.65; 95% CI 1.90-3.68), endometrial cancer (HR 3.53; 95% CI 2.76-4.53), hypothyroidism (HR 1.29; 95% CI 1.19-1.40), pulmonary fibrosis (HR 1.84; 95% CI 1.12-3.02), and hyperlipidemia (HR 1.24; 95% CI 1.20-1.28) remained significantly elevated after more than 5 years since diagnosis. Optimal care for breast cancer survivors requires close collaboration between oncologists and allied health care professionals to identify and manage the long-term morbidity and mortality associated with these chronic conditions. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | NATURE RESEARCH | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.title | Temporal patterns of chronic disease incidence after breast cancer: a nationwide population-based cohort study | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000776953600038 | - |
dc.identifier.doi | 10.1038/s41598-022-09542-w | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, v.12, no.1 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85127376637 | - |
dc.citation.title | SCIENTIFIC REPORTS | - |
dc.citation.volume | 12 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Seo, Hwa Jeong | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordPlus | NEOPLASMS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.